1. covid-19 patients that do not require hospitalization (outpatient setting). 2. patients who are participating in other therapeutic clinical trials. 3. covid-19 patients who have received convalescent plasma treatment. 4. critical disease covid- 19 patients (respiratory failure, septic shock, and/or multiple organ dysfunction, admission pao2/fio2 ratio \< 100). 5. previously snake bitten individuals that received any type of equine hyperimmune serum treatment. 6. history of an allergic reaction due to contact or exposure to horses. 7. pregnant or breastfeeding women. 8. patients who, at the investigator´s discretion, are not likely to comply with study indications and procedures. 9. patients currently undergoing hemodialysis in a renal support program. 10. individuals who were previously classified by their treating physicians (prior to the covid-19 diagnosis), of having an unfavorable prognosis with a short lifespan due to a concomitant disease other than the study disease.

1. covid-19 patients that do not require hospitalization (outpatient setting). 2. patients who are participating in other therapeutic clinical trials. 3. covid-19 patients who have received convalescent plasma treatment. 4. critical disease covid- 19 patients (respiratory failure, septic shock, and/or multiple organ dysfunction, admission pao2/fio2 ratio \< 100). 5. previously snake bitten individuals that received any type of equine hyperimmune serum treatment. 6. history of an allergic reaction due to contact or exposure to horses. 7. pregnant or breastfeeding women. 8. patients who, at the investigator´s discretion, are not likely to comply with study indications and procedures. 9. patients currently undergoing hemodialysis in a renal support program. 10. individuals who were previously classified by their treating physicians (prior to the covid-19 diagnosis), of having an unfavorable prognosis with a short lifespan due to a concomitant disease other than the study disease.

covid-19 patients that do not require hospitalization (outpatient setting). patients who are participating in other therapeutic clinical trials. covid-19 patients who have received convalescent plasma treatment. critical disease covid- 19 patients (respiratory failure, septic shock, and/or multiple organ dysfunction, admission pao2/fio2 ratio < 100). previously snake bitten individuals that received any type of equine hyperimmune serum treatment. history of an allergic reaction due to contact or exposure to horses. pregnant or breastfeeding women. patients who, at the investigator´s discretion, are not likely to comply with study indications and procedures. patients currently undergoing hemodialysis in a renal support program. individuals who were previously classified by their treating physicians (prior to the covid-19 diagnosis), of having an unfavorable prognosis with a short lifespan due to a concomitant disease other than the study disease.

covid-19 patients that do not require hospitalization (outpatient setting). patients who are participating in other therapeutic clinical trials. covid-19 patients who have received convalescent plasma treatment. critical disease covid- 19 patients (respiratory failure, septic shock, and/or multiple organ dysfunction, admission pao2/fio2 ratio < 100). previously snake bitten individuals that received any type of equine hyperimmune serum treatment. history of an allergic reaction due to contact or exposure to horses. pregnant or breastfeeding women. patients who, at the investigator´s discretion, are not likely to comply with study indications and procedures. patients currently undergoing hemodialysis in a renal support program. individuals who were previously classified by their treating physicians (prior to the covid-19 diagnosis), of having an unfavorable prognosis with a short lifespan due to a concomitant disease other than the study disease.

1. covid-19 patients that do not require hospitalization (outpatient setting). 2. patients who are participating in other therapeutic clinical trials. 3. covid-19 patients who have received convalescent plasma treatment. 4. critical disease covid- 19 patients (respiratory failure, septic shock, and/or multiple organ dysfunction, admission pao2/fio2 ratio < 100). 5. previously snake bitten individuals that received any type of equine hyperimmune serum treatment. 6. history of an allergic reaction due to contact or exposure to horses. 7. pregnant or breastfeeding women. 8. patients who, at the investigator´s discretion, are not likely to comply with study indications and procedures. 9. patients currently undergoing hemodialysis in a renal support program. 10. individuals who were previously classified by their treating physicians (prior to the covid-19 diagnosis), of having an unfavorable prognosis with a short lifespan due to a concomitant disease other than the study disease.

1. covid-19 patients that do not require hospitalization (outpatient setting). 2. patients who are participating in other therapeutic clinical trials. 3. covid-19 patients who have received convalescent plasma treatment. 4. critical disease covid- 19 patients (respiratory failure, septic shock, and/or multiple organ dysfunction, admission pao2/fio2 ratio < 100). 5. previously snake bitten individuals that received any type of equine hyperimmune serum treatment. 6. history of an allergic reaction due to contact or exposure to horses. 7. pregnant or breastfeeding women. 8. patients who, at the investigator´s discretion, are not likely to comply with study indications and procedures. 9. patients currently undergoing hemodialysis in a renal support program. 10. individuals who were previously classified by their treating physicians (prior to the covid-19 diagnosis), of having an unfavorable prognosis with a short lifespan due to a concomitant disease other than the study disease.